Gradient Investments’s Galectin Therapeutics GALT Stock Holding History

Gradient Investments’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-3,800	Closed	-$6.31K	–	1461
2023 Q4	$6.31K	Hold	3,800	–	–	﹤0.01%	936
2023 Q3	$7.3K	Hold	3,800	–	–	﹤0.01%	868
2023 Q2	$5.47K	Hold	3,800	–	–	﹤0.01%	938
2023 Q1	$7.98K	Hold	3,800	–	–	﹤0.01%	856
2022 Q4	$4.29K	Hold	3,800	–	–	﹤0.01%	958
2022 Q3	$6K	Hold	3,800	–	–	﹤0.01%	909
2022 Q2	$5K	Hold	3,800	–	–	﹤0.01%	891
2022 Q1	$6K	Hold	3,800	–	–	﹤0.01%	860
2021 Q4	$8K	Hold	3,800	–	–	﹤0.01%	843
2021 Q3	$15K	Hold	3,800	–	–	﹤0.01%	688
2021 Q2	$12K	Hold	3,800	–	–	﹤0.01%	727
2021 Q1	$8K	Hold	3,800	–	–	﹤0.01%	804
2020 Q4	$10K	Hold	3,800	–	–	﹤0.01%	694
2020 Q3	$10K	Hold	3,800	–	–	﹤0.01%	697
2020 Q2	$12K	Hold	3,800	–	–	﹤0.01%	614
2020 Q1	$7K	Hold	3,800	–	–	﹤0.01%	715
2019 Q4	$11K	Buy	+3,800	New	+$13.2K	﹤0.01%	671

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

AWS

Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Gradient Investments's GALT Position: Q1 2024 in Review

Gradient Investments sold out of Galectin Therapeutics (GALT) in Q1 2024, closing a stake of 3,800 shares — an estimated $6.31K sold.

Gradient Investments first reported a position in GALT in Q4 2019 and held it in 17 quarters. The position peaked at $15K in Q3 2021. 59 funds tracked by Wall St. Rank hold GALT as of Q1 2024.

Gradient Investments reported no remaining Galectin Therapeutics position as of Q1 2024 after selling out during the quarter.
Gradient Investments sold 3,800 Galectin Therapeutics shares in Q1 2024, an estimated $6.31K.
Gradient Investments first reported a position in Galectin Therapeutics in Q4 2019 and held it in 17 quarters.
Gradient Investments's Galectin Therapeutics position peaked at $15K in Q3 2021.
59 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2024.

Based on Gradient Investments's 13F filing for Q1 2024, filed 23 Apr 2024.